Potential drug-drug interactions in outpatients with depression of a psychiatry department

被引:6
|
作者
Chen, Yang [1 ]
Ding, Lijun [1 ]
机构
[1] Xiamen Xianyue Hosp, Xiamen 361001, Fujian, Peoples R China
关键词
Drug -drug interactions; Potential drug -drug interactions; Polypharmacy; Depression; Psychotropic drugs; Outpatients; Ding); GENDER-DIFFERENCES; TREATMENT STRATEGY; RISK-FACTORS; PREVALENCE;
D O I
10.1016/j.jsps.2022.12.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: This study aims to explore the prevalence and associated risk factors for potential drug-drug interactions (pDDIs) in prescriptions among outpatients with depression, and report the widespread rel-evant drug interactions. Methods: The cross-sectional retrospective study was conducted on outpatients in a psychiatric hospital. We included prescriptions of outpatients with a principal diagnosis of depression from April 1st to June 30th in 2021. The patients were >= 18 years old and treated with two or more drugs including at least one psychotropic drug. pDDIs were detected and identified mainly using Medscape's drug interactions checker. Gender, the number of concomitant drugs, age and diagnosis were analysed as potential risk fac-tors for the occurrence of pDDIs by logistic regression. Results: A total of 13,617 prescriptions were included in the present analysis, and 4222 prescriptions (31.0%) were at risk of 8557 pDDIs. The risk of pDDIs in patients who were prescribed 4-6 drugs (OR: 3.49, 95% CI: 3.11-3.91, p < 0.001) or 7 or more drugs simultaneously (OR: 7.86, 95% CI: 1.58-39.04, p < 0.05) increased compared with patients prescribed 2-3 drugs. Patients with recurrent depressive dis-orders (OR: 1.18, 95% CI: 1.02-1.36, p < 0.05) had an increased risk of pDDIs compared with patients with depressive episodes. In terms of severity of pDDIs identified by Medscape's drug interactions checker, 0.7%, 16.4%, 77.5% and 5.4% of pDDIs were classified as contraindicated, serious, monitor closely and minor, respectively. The most common pDDI was escitalopram + quetiapine (374 prescriptions), which was classified as serious and monitor closely due to different mechanisms of interaction. Increased cen-tral nervous system (CNS)-depressant effect was the most frequent potential clinical adverse outcome of the identified pDDIs. Conclusions: pDDIs in outpatients with depression were prevalent in this retrospective study. The num-ber of concomitant drugs and severity of the disease were important risk factors for pDDIs. The pDDIs of the category monitor closely were the most common, and the CNS-depressant effect was the most fre-quent potential clinical adverse outcome.(c) 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
下载
收藏
页码:207 / 213
页数:7
相关论文
共 50 条
  • [41] Preclinical Evaluation of Cudetaxestat for Potential Drug-Drug Interactions
    Yu, W.
    Rajagopalan, R.
    Lin, J.
    Ibrahim, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [42] Potential drug-drug interactions in hospitalised haematological patients
    Fernandez de Palencia Espinosa, Ma Angeles
    Diaz Carrasco, Ma Sacramento
    Sanchez Salinas, Andres
    de la Rubia Nieto, Amelia
    Espuny Miro, Alberto
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (06) : 443 - 453
  • [43] Evaluation of potential drug-drug interactions in a pediatric population
    Bebitoglu, Berna Terzioglu
    Oguz, Elif
    Nuhoglu, Cagatay
    Dalkilic, Ayse Ela Kurtdan
    Cirtlik, Pelin
    Temel, Fatime
    Hodzic, Ajla
    TURK PEDIATRI ARSIVI-TURKISH ARCHIVES OF PEDIATRICS, 2020, 55 (01): : 30 - 38
  • [44] Assessment of potential drug-drug interactions at hospital discharge
    Bertoli, R.
    Bissig, M.
    Caronzolo, D.
    Odorico, M.
    Pons, M.
    Bernasconi, E.
    SWISS MEDICAL WEEKLY, 2010, 140
  • [45] Prevalence of potential drug-drug interactions in Slovenia in 2013
    Jazbar, Janja
    Locatelli, Igor
    Kos, Mitja
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (02) : 408 - 409
  • [46] Analysis of potential drug-drug interactions in hospitalized patients
    Wieczorek, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (06) : 1550 - 1550
  • [47] Data mining for potential adverse drug-drug interactions
    Hammann, Felix
    Drewe, Juergen
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (05) : 665 - 671
  • [48] Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions
    Vazquez, Marta
    Garcia-Carnelli, Carlos
    Maldonado, Cecilia
    Fagiolino, Pietro
    CANNABINOIDS AND SLEEP: MOLECULAR, FUNCTIONAL AND CLINICAL ASPECTS, 2021, 1297 : 27 - 42
  • [49] Milnacipran Has Low Potential for Drug-Drug Interactions
    Periclou, Antonia
    Coutts, Stephen M.
    Rao, Sriniuas G.
    Palmer, Robert H.
    Thacker, Kim
    Trugman, Joel
    NEUROLOGY, 2009, 72 (11) : A212 - A212